Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy.

Individual differences in chemosensitivity and clinical outcome of non-small-cell lung carcinoma (NSCLC) patients can be influenced by host-inherited factors. We investigated the impact of XRCC1 Arg194Trp, XRCC1 Arg280His, XRCC1 Arg399Gln, XPD Arg156Arg, XPD Asp312Asn, XPD Asp711Asp, and XPD Lys751Gln gene polymorphisms on treatment efficacy in 375 NSCLC patients on platinum-based chemotherapy. We also examined progression-free survival and overall survival. The gene polymorphisms were analyzed by duplex PCR. The patients with XRCC1 399A/A had a significantly better response to chemotherapy. Individuals with XPD 711 Asp and XPD 312 Asn alleles responded poorly to chemotherapy when compared with the wide-type genotype. The adjusted hazard ratio (HR) in the Cox regression model was calculated. The XRCC1 399A/A polymorphism was associated with better progression free survival and overall survival of NSCLC patients (HR=0.61 and 0.55). On the other hand, the XPD 711 Asp allele was associated with poorer progression free survival and overall survival compared to the C/C genotype, with HRs of 1.89 and 1.90. The XPD 312 Asn allele was found to be associated with non-significantly reduced survival of NSCLC patients (HR = 1.73). In conclusion, we found the polymorphisms of XRCC1 and XPD to be related to the efficacy of platinum-based chemotherapy in NSCLC patients. This information should aid in therapeutic decisions for individualized therapy in NSCLC cases.

[1]  D. Butkiewicz,et al.  Influence of DNA repair gene polymorphisms on prognosis in inoperable non‐small cell lung cancer patients treated with radiotherapy and platinum‐based chemotherapy , 2012, International journal of cancer.

[2]  B. Massuti,et al.  Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer , 2012, Cancer Chemotherapy and Pharmacology.

[3]  Ninghan Feng,et al.  Impact of Two Common Xeroderma Pigmentosum Group D (XPD) Gene Polymorphisms on Risk of Prostate Cancer , 2012, PloS one.

[4]  R. Wu,et al.  Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[5]  J. Shih,et al.  Genetic Polymorphism of XRCC1 Arg399Gln Is Associated With Survival in Non–Small-Cell Lung Cancer Patients Treated With Gemcitabine/Platinum , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  P. Srivastava,et al.  Gene variants of XRCC4 and XRCC3 and their association with risk for urothelial bladder cancer , 2012, Molecular Biology Reports.

[7]  Ye Zhang,et al.  [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer]. , 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[8]  Jun Liang,et al.  Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. , 2011, Swiss medical weekly.

[9]  R. Booton,et al.  No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. , 2011, Lung cancer.

[10]  A. Cittadini,et al.  Polymorphisms of the CYP1A1, CYP2E1 and XRCC1 genes and cancer risk in a Southern Italian population: a case-control study. , 2011, Anticancer research.

[11]  Yi Shi,et al.  Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis , 2011, Medical oncology.

[12]  Y. Nakagawa,et al.  Effect of genetic polymorphisms related to DNA repair and the xenobiotic pathway on the prognosis and survival of gastric cancer patients. , 2011, Anticancer research.

[13]  Thomas J. Smith,et al.  [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer]. , 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[14]  Edward S. Kim,et al.  Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. , 2009, Chest.

[15]  M. Pincus,et al.  Conformational effects of a common codon 751 polymorphism on the C-terminal domain of the xeroderma pigmentosum D protein , 2009, Journal of carcinogenesis.

[16]  F. Schmidt.  Meta-Analysis , 2008 .

[17]  So-Yeon Park,et al.  The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[18]  K. Vasquez,et al.  Mismatch repair participates in error‐free processing of DNA interstrand crosslinks in human cells , 2005, EMBO reports.

[19]  S. Ahrendt,et al.  The XRCC1 codon 399 Gln allele is associated with adenine to guanine p53 mutations in non-small cell lung cancer. , 2003, Mutation research.

[20]  C I Amos,et al.  Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. , 2001, Cancer research.

[21]  H. Bartelink,et al.  DNA‐adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy , 2000, International journal of cancer.

[22]  D. Bell,et al.  XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. , 1999, Cancer research.

[23]  Xian-Tao Zeng,et al.  Association between XPD Asp312Asn polymorphism and esophageal cancer susceptibility: a meta-analysis. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[24]  J. S. Júnior,et al.  cell lung cancer patients in Brazil , 2012 .

[25]  S. Alpar,et al.  CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients. , 2010, Neoplasma.

[26]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[27]  J. Jen,et al.  Mutations in Non-Small Cell Lung Cancer p 53 Frequency of Alcohol Consumption and Cigarette Smoking Increase the Updated , 2000 .